@jfais20 · Long VSTM · The Analysts

$VSTM - nice delayed reaction, market digesting the offering & realizing the tolerability & efficacy edge in G12D vs $RVMD daraxonrasib is real (or at least the possibility of it being real merits a rerating) + CRC optionality

Read asLong VSTM

Since the call—

unrankedThe analyst's rank today

High · 0.91Confidence

Thu, Oct 15Tweeted

Fri, Oct 16 closeCounted from

4% of the basket · day 4fades out by Nov 26

Rank per close

—

Oct 18

—

Oct 19